CRISPR/Cas9 gene editing

Applied StemCell is a biotechnology company founded in 2008 that provides genome engineering technologies and iPSC expertise for cell therapy discovery, development, and manufacturing. The company offers proprietary TARGATT large knock-in technology, CRISPR/Cas9 and Mad7 gene editing, iPSC services, and cGMP cell banking and manufacturing.

cell line engineeringcGMP cell bankingcGMP cell manufacturinggenome engineeringiPSC differentiationiPSC gene editingiPSC generationMad7 gene editingTARGATT large knock-in technology

Chemestmed is an Estonian biotech company developing first-in-class drugs to treat CNS and metabolic diseases and disorders. It works in epitranscriptomics, developing a technological platform for discovery of novel drugs based on mRNA regulation in cells, including small-molecule activators targeting the METTL3/METTL14 methyltransferase complex to enhance RNA m⁶A methylation.

cell-based assay developmentenzyme assaysepitranscriptomics researchin vitro cell culturemolecular modelingNMR analysisorganic synthesisquantum chemistry calculationssmall molecule drug discoveryvirtual screening

Curi Bio is a science-first organization that develops human-relevant platforms integrating human cells, systems, and data to accelerate the discovery of new medicines. Its human iPSC-based products and services enable scientists to build mature and predictive human iPSC-derived tissues, with a focus on cardiac, musculoskeletal, and neuromuscular models, for discovery, safety testing, and efficacy testing of new therapeutics. It also offers contract research services through the Curi Engine.

3D tissue engineeringContract Research Servicesdirected differentiationdrug screeningfunctional assaysiPSC expansion and bankingpotency assays